Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial
Victoria P. Werth(Philadelphia VA Medical Center), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Michael Weiswasser(Bristol-Myers Squibb (United States)), MARK B. STERN(Bristol-Myers Squibb (United States)), Peter E. Lipsky(Ampel BioSolutions (United States)), Joan T. Merrill(Oklahoma Medical Research Foundation), Shimon Korish(Bristol-Myers Squibb (United States)), Richard Furie(Hofstra University), Stan Z. Li(Westlake University), Ronald van Vollenhoven(Amsterdam University Medical Centers), Peter Schäfer(Bristol-Myers Squibb (United States)), Thomas E. Dorner(German Rheumatism Research Centre)
Cited by 7
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913